MGNX

3.51

1.68% -0.06

Handel nachbörslich: 3.55 0.04 +1.14%

Macrogenics Inc (MGNX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.57

Offen:

$3.58

24-Stunden-Volumen:

550.61K

Relative Volume:

0.84

Marktkapitalisierung:

$222.80M

Einnahmen:

$56.91M

Nettoeinkommen (Verlust:

$-9.06M

KGV:

29.25

EPS:

0.12

Netto-Cashflow:

$-79.97M

1W Leistung:

-20.05%

1M Leistung:

-12.47%

6M Leistung:

-19.59%

1J Leistung:

-53.75%

1-Tages-Spanne:

$3.50

$3.71

1-Wochen-Bereich:

$3.50

$4.39

52-Wochen-Spanne:

$2.9511

$21.88

Macrogenics Inc Stock (MGNX) Company Profile

Firmenname

Macrogenics Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

301-251-5172

Adresse

9704 MEDICAL CENTER DRIVE, Rockville, MD

Mitarbeiter

339

Twitter

@macrogenics

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

MGNX's Discussions on Twitter

Vergleichen Sie MGNX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MGNX	3.51	222.80M	56.91M	-9.06M	-79.97M	0.12
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-20	Hochstufung	Citigroup	Neutral → Buy
2023-11-07	Hochstufung	Guggenheim	Neutral → Buy
2023-03-17	Herabstufung	Guggenheim	Buy → Neutral
2022-11-22	Herabstufung	Cowen	Outperform → Market Perform
2022-11-14	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-07-18	Herabstufung	SMBC Nikko	Outperform → Neutral
2022-07-11	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-05-04	Herabstufung	Guggenheim	Buy → Neutral
2022-02-28	Hochstufung	Citigroup	Neutral → Buy
2022-02-11	Eingeleitet	BMO Capital Markets	Outperform
2022-02-04	Eingeleitet	SMBC Nikko	Outperform
2021-11-17	Fortgesetzt	Guggenheim	Buy
2021-10-19	Eingeleitet	JMP Securities	Mkt Outperform
2021-10-15	Fortgesetzt	BTIG Research	Buy
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-12	Hochstufung	Barclays	Underweight → Overweight
2020-12-22	Fortgesetzt	H.C. Wainwright	Buy
2020-08-03	Herabstufung	Citigroup	Buy → Neutral
2020-06-01	Hochstufung	Guggenheim	Neutral → Buy
2020-05-26	Bestätigt	H.C. Wainwright	Buy
2020-03-04	Eingeleitet	Barclays	Underweight
2019-12-19	Eingeleitet	Cantor Fitzgerald	Overweight
2019-12-18	Eingeleitet	Cantor Fitzgerald	Overweight
2019-11-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-11-20	Fortgesetzt	Guggenheim	Neutral
2019-05-03	Hochstufung	Wedbush	Neutral → Outperform
2019-04-12	Eingeleitet	Guggenheim	Neutral
2019-02-07	Hochstufung	Citigroup	Sell → Buy
2019-02-07	Herabstufung	Wedbush	Outperform → Neutral
2019-02-06	Hochstufung	Raymond James	Underperform → Mkt Perform
2019-02-04	Herabstufung	Citigroup	Neutral → Sell
2018-12-10	Herabstufung	Raymond James	Outperform → Underperform
2018-09-10	Fortgesetzt	BTIG Research	Buy
2018-05-31	Eingeleitet	Evercore ISI	Outperform
2018-03-05	Eingeleitet	H.C. Wainwright	Buy
2017-03-31	Eingeleitet	Raymond James	Outperform

Alle ansehen

Macrogenics Inc Aktie (MGNX) Neueste Nachrichten

Nov 14, 2024

MacroGenics' SWOT analysis: biotech stock faces pipeline hurdles amid cash strength - Investing.com India

Nov 14, 2024

Nov 11, 2024

MacroGenics downgraded to Market Perform from Outperform at JMP Securities - TipRanks

Nov 07, 2024

Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights - Benzinga

Nov 07, 2024

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024

MacroGenics (NASDAQ:MGNX) Rating Lowered to "Market Perform" at JMP Securities - MarketBeat

Nov 07, 2024

MacroGenics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024

Nov 06, 2024

MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024

MacroGenics (MGNX) to Present at Guggenheim and Stifel Healthcare Conferences | MGNX Stock News - StockTitan

Nov 06, 2024

Earnings call: MacroGenics reports a revenue jump to $110.7 million By Investing.com - Investing.com South Africa

Nov 06, 2024

Earnings call: MacroGenics reports a revenue jump to $110.7 million - Investing.com India

Nov 06, 2024

MacroGenics Margenza rights sale a positive, says Leerink - TipRanks

Nov 06, 2024

MacroGenics (NASDAQ:MGNX) Receives Neutral Rating from HC Wainwright - MarketBeat

Nov 06, 2024

MacroGenics Inc earnings beat by $0.69, revenue topped estimates - Investing.com Australia

Nov 06, 2024